Effect of specimen type on free immunoglobulin light chains analysis on the Roche Diagnostics cobas 8000 analyzer by unknown
Nelson et al. SpringerPlus  (2015) 4:760 
DOI 10.1186/s40064-015-1546-x
RESEARCH
Effect of specimen type on free 
immunoglobulin light chains analysis on the 
Roche Diagnostics cobas 8000 analyzer
Louis S. Nelson, Bryan Steussy, Cory S. Morris and Matthew D. Krasowski*
Abstract 
 The measurement of free immunoglobulin light chains is typically performed on serum; however, the use of alterna-
tive specimen types has potential benefits. Using the Freelite™ kappa and lambda free light chains assay on a Roche 
Diagnostics cobas 8000 c502 analyzer, we compared three specimen types (serum, EDTA-plasma and lithium heparin 
plasma separator gel-plasma) on 100 patients. Using Deming regression and eliminating outliers (limiting data to light 
chain concentrations below 400 mg/L), the three specimen types showed comparable results for kappa light chain 
concentration, lambda light chain concentration, and kappa/lambda ratio with slopes close to 1.0 and y-intercepts 
close to zero. EDTA-plasma showed slightly more positive bias relative to serum than lithium heparin. Analysis using 
EDTA-plasma and lithium heparin plasma showed comparable linearity, precision, and temperature stability. A single 
sample showing hook effect (not in the comparison set) gave comparable results using either plasma specimen type. 
For the Freelite™ kappa and lambda free light chains assay, both EDTA-plasma or lithium heparin-plasma can serve as 
acceptable substitutes for serum, at least for the Roche cobas 8000 analyzer.
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Background
Measurement of kappa and lambda free immunoglobu-
lin light chains in serum has been shown to be valuable 
in the diagnosis and management of a variety of dis-
eases, especially plasma cell disorders such as multiple 
myeloma, Waldenström’s macroglobulinemia, AL amy-
loidosis, and light chain deposition diseases (Bradwell 
et  al. 2001; Dimopoulos et  al. 2011; Dispenzieri et  al. 
2009, 2010; Hoedemakers et  al. 2011; Katzmann et  al. 
2005; Lachmann et  al. 2003; Morris et  al. 2007; Snozek 
et al. 2008; Tosi et al. 2013). Serum free light chain analy-
sis is often used in conjunction with serum and urine 
protein electrophoresis (Hoedemakers et  al. 2011; Kim 
et  al. 2014; McTaggart et  al. 2013). Serum is the man-
datory specimen for protein electrophoresis; thus, the 
same serum specimen is often used for measurement of 
free light chains. However, analysis of plasma may have 
potential practical advantages compared to serum. For 
example, the ability to use plasma as a specimen for free 
light chain analysis may limit number of blood collec-
tion tubes needed during phlebotomy for some patients 
(e.g., if plasma but not serum is needed for other tests co-
ordered for a patient) or to allow add-on orders for free 
light chain analysis if serum is not available as a pre-exist-
ing specimen (Nelson et al. 2015). The ability to run free 
light chain analysis on automated chemistry instrumen-
tation typically allows for faster turnaround time than 
protein electrophoresis, which requires more specialized 
instrumentation and result interpretation.
In this study we compared the differences between 
serum and plasma for measurement of kappa and lambda 
free light chains using the Freelite™ serum free light chain 
assays on a Roche Diagnostics cobas 8000 c502 analyzer. 
Plasma specimens obtained from ethylenediaminetet-
raacetic acid (EDTA)-anticoagulated tubes and lithium 
heparin plasma separator tubes (PST) were used for the 
comparisons. A previous study has compared plasma 
versus serum for another marketed free light chain assay 
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(N Latex FLC) and showed similar results using either 
specimen type (te Velthuis et  al. 2011). Another study 
compared serum versus serum separator gel and lithium 
heparin plasma samples for the Freelite™ assay on a Dade 
Behring BNII analyzer (Hansen et  al. 2012). However, 
there is no published study doing the same comparison 
for the Freelite™ assay on the Roche cobas system, and 
the manufacturer instructions for the Freelite™ assay on 
this analytical platform only list serum as the acceptable 
specimen type (Freelite™ Human Kappa Free and Human 
Lambda Free Light Chains package insert.).
Experimental
Sample collection and processing for comparison studies
This study had approval from the University of Iowa 
Institutional Review Board (protocol #201407792). Test-
ing was performed in the University of Iowa Hospitals 
and Clinics (UIHC) core clinical laboratory. The lay-
out and informatics of this clinical laboratory has been 
detailed in previous publications (Krasowski et al. 2014, 
2015). The inclusion criteria were: (1) patient who had 
free light chain analysis performed on a serum speci-
men, (2) EDTA-anticoagulated and lithium heparin PST 
specimens drawn on patient for clinical testing during 
same phlebotomy encounter, and (3) sufficient speci-
men remaining in the EDTA and PST specimens for light 
chain analysis after performance of provider-ordered 
clinical testing. The details on the three specimen types 
were: BD Vacutainer® red top silica clot activator coated 
tube (BD Diagnostics, Franklin Lakes, NJ), BD Vacu-
tainer® light green top plasma separator tubes (PST™) 
containing polymer gel and lithium heparin  (BD Diag-
nostics), and BD Vacutainer® pink top spray coated 
K2EDTA tube (BD Diagnostics). No extra tubes were 
drawn on any patient for purposes of this study, i.e., all 
analyses used pre-existing specimens leftover from clini-
cal testing that would otherwise have been discarded.
Upon completion of the clinically ordered tests, the 
specimens were transferred to a refrigerator for storage 
using a Roche Diagnostics (Indianapolis, IN) P701 auto-
mated archival retrieval system (Nelson et al. 2015). Sam-
ples were stored for up to 16 h until they were retrieved 
for use in the study. When samples were retrieved, they 
were centrifuged and loaded on to the Roche Diagnostics 
cobas 8000 Modular Analytics System c502 analyzer and 
assayed using the Freelite™ kappa and lambda free light 
chains assay (Freelite™ Human Kappa Free and Human 
Lambda free light chains package insert 2001).
Following the package insert procedure, kappa light 
chain measurements for serum specimens are lin-
ear to 56.25  mg/L. Values that exceed 56.25  mg/L are 
treated with ×10 dilution with saline. Values that still 
exceed linearity require a manual ×21 dilution with 
saline. Lambda light chain measurements are linear to 
93.33  mg/L. Similar to the procedure with kappa light 
chains, lambda light chain values that exceed 93.33 mg/L 
are treated with ×10 dilution with saline. Values that 
still exceed linearity require a manual ×21 dilution with 
saline.
Linearity studies
Linearity was determined according to CLSI guide-
line EP6A (Clinical and Laboratory Standards Institute 
2003) using plasma samples just above the upper meas-
uring range for serum, i.e., 56.25  mg/L for kappa and 
93.33 mg/L for lambda. At least 10 dilutions of 90–2.5 % 
were measured for both EDTA-plasma and lithium hepa-
rin PST matrices. Five replicates for each dilution were 
measured. The mean result was analyzed by linear and 
cubic analysis. Fits were evaluated using the Microsoft 
Excel add-in Analyze-it®.
Method imprecision
The precision study was performed according to CLSI 
EP5-A2 guideline (Clinical and Laboratory Standards 
Institute 2004). Plasma pools were made from routine 
patient samples that had no detectable monoclonal bands 
with serum electrophoresis and immunotyping.
Reference ranges and medical decision levels
The normal (reference) ranges for the free light chains 
following manufacturer recommendations in the pack-
age insert are: kappa (3.30–19.40  mg/L), lambda (5.71–
26.30 mg/L), kappa/lambda ratio (0.26–1.65). The lower 
and upper limits of the reference ranges for serum in 
the assay package insert were considered the medical 
decision levels (MDL). Assay measurement using serum 
(specimen type recommended in package insert) was 
considered the gold standard.
Statistical analysis
Linear regression and statistical analysis was performed 
using EP Evaluator release 11 (Data Innovations, Inc., 
South Burlington, VT). Deming linear regression was 
performed. Identification of outliers used an algorithm in 
EP Evaluator that identifies points whose distance from 
the regression line exceeds 10 times the standard error of 




The precision of the kappa and lambda light chain assays 
at different levels of control material are summarized in 
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Table  1. The coefficient of variation (CV) was less than 
5  % for the within- and between-run precision studies. 
The results of the precision studies for plasma pools are 
summarized in Fig. 1. The  % CV was generally 5–7 % or 
less across most of the measuring range except for kappa 
and lambda concentrations less than 5 mg/L. At concen-
trations near 1 mg/L, the  % CV values approach 20 %.
Linearity studies
Serial dilutions of samples with a concentration just 
above the measuring range (56.25  mg/L for kappa and 
93.33  mg/L for lambda) were prepared. For kappa, lin-
earity was confirmed between 1.0 and 56.25  mg/L for 
both EDTA-plasma and lithium heparin PST (maxi-
mum difference between linear and cubic fit of 18.8 %). 
For lambda, linearity was confirmed between 0.8 and 
93.33  mg/L (maximum difference between linear and 
cubic fit of 17.4 %).
Method comparison
Samples from a total of 100 patients met the inclusion cri-
teria for this study with sufficient serum, EDTA-plasma, 
and lithium heparin-plasma for free light chain analysis. 
Scatterplots for kappa, lambda and kappa/lambda ratio 
are shown for all 100 samples in Fig. 2 and for the subset 
of kappa and lambda values less than 400 mg/L in Fig. 3. 
By classifying the specimens on the basis of the reference 
intervals, there was 84 and 86 % agreement, respectively, 
between serum and either EDTA-plasma or lithium 
heparin PST specimens for the kappa light chain assay 
(Table  2). The agreement rate was 95  % for the lambda 
light chain assays (serum versus either EDTA-plasma and 
lithium heparin plasma) and 98 % for the kappa/lambda 
ratio (serum versus either EDTA-plasma and lithium 
heparin plasma) (Table 2). All of the discrepancies with 
respect to reference interval were the result of the plasma 
result being higher than the value obtained from serum 
(Table 2). A summary of the specimens showing discrep-
ancies is in Table 3, with clinical history and age/gender 
of patient described.
Comparison between serum and the two plasma speci-
men types was done by Deming linear regression. Out-
liers identified in the analysis were predominantly due 
to specimens with kappa and lambda concentrations 
exceeding 400 mg/L (thus Fig. 3 is restricted to kappa and 
lambda concentrations less than 400  mg/L). The outli-
ers are summarized in Table 4 (some of these overlapped 
with the specimens described in Table 3).
Linear regression parameters are summarized in 
Table  5. For all comparisons, slopes are close to 1.0. A 
slightly more noticeable positive bias was noted with 
EDTA-plasma versus serum. For lithium heparin PST 
versus serum, the confidence intervals for the slope and 
y-intercept for kappa light chain, lambda light chain, 
and kappa/lambda ratio overlapped with 1.000 and 0.0, 
respectively. At the MDL, the confidence intervals over-
lapped with that for serum.
Stability studies
Stability studies were performed for pooled plasma sam-
ples stored either refrigerated (4 °C) or frozen at −20 °C. 
Results were generally within 10  % of those obtained 
at initial measurement (Fig.  4). The highest variability 
was seen at kappa and lambda concentrations less than 
10 mg/L, similar to that described above for the precision 
studies (Fig. 1).
Antigen excess
During the time period of study, a single specimen was 
analyzed that showed marked hook effect for lambda 
light chain. This specimen was from a patient whose 
specimens had previously shown hook effect during 
Table 1 Precision using two different levels of  control 
material
CV coefficient of variation
Light chain 
assay
Mean (mg/L) Within-run  





Kappa 17.4 2.9 4.8
Kappa 34.1 3.5 4.6
Lambda 30.0 3.4 4.9
Lamdba 63.3 2.6 4.5
Fig. 1 Precision profile of the total coefficient of variation (CV) 
estimated according to CLSI EP5-A2. Squares (open and filled) indicate 
kappa and lambda concentrations, respectively, using EDTA-plasma. 
Circles (open and filled) indicate kappa and lambda concentrations, 
respectively, using lithium heparin plasma separator tubes
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Fig. 2 Comparisons of serum versus EDTA-plasma or lithium heparin-plasma separator tube as specimens for measurement of free light chains 
(n = 100). The graphs are scatter plots of data for kappa concentration (a, b), lambda concentration (c, d), and kappa/lambda ratio (e, f). The line is the line 
of identity
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Fig. 3 Comparisons of serum versus EDTA-plasma or lithium heparin-plasma separator tube as specimens for measurement of free light chains 
showing subset of data. The graphs are scatter plots of data for kappa concentration (a, b; restricted to 400 mg/L or less), lambda concentration (c, 
d; restricted to 400 mg/L or less), and kappa/lambda ratio (e, f; restricted to 100 or less). The line is the line of identity
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multiple occasions. Specimens from this patient were not 
in the comparison studies (occurred after those studies 
completed). The hook effect was comparable in EDTA-
plasma and lithium heparin PST specimen. In particu-
lar, the apparent lambda light chain concentration in 
undiluted specimens was 89.3 and 89.8  mg/L, respec-
tively, for EDTA-plasma and lithium heparin PST 
specimens. Dilution analysis shown the actual lambda 
concentrations to be 4053 and 3862 mg/L, respectively, in 
these two sample types.
Table 2 Concordance tables between plasma and serum for light chain analysis




Kappa EDTA vs. serum 84 11 5
Kappa Lithium heparin PST vs. serum 86 10 4
Lambda EDTA vs. serum 98 2 0
Lambda Lithium heparin PST vs. serum 98 1 1
Kappa/lambda ratio EDTA vs. serum 95 1 4
Kappa/lambda ratio Lithium heparin PST vs. serum 95 1 4
Table 3 Samples with discrepancy with respect to reference intervals















 60 Y M, multiple myeloma, IgG kappa 2.6 5.9 0.44 4.4 5.8 0.76 3.8 6.2 0.61
 66 Y F, multiple myeloma, IgG lambda 2.7 5.8 0.47 4.4 6.6 0.67 3.7 6.8 0.54
 44 Y F, multiple myeloma, IgG lambda 17.8 40.0 0.45 20.8 36.8 0.57 20.2 39.5 0.51
 60 Y F, multiple myeloma, IgG lambda 18.8 10.7 1.76 20.8 11.6 1.79 20.1 11.1 1.81
 61 Y M, multiple myeloma, IgG kappa 2.8 6.1 0.46 4.1 6.5 0.63 4.1 6.1 0.67
 51 Y M, multiple myeloma, IgG kappa 2.7 5.8 0.47 5.1 6.2 0.82 5.3 6.2 0.85
 86 Y F, multiple myeloma, lambda light chain 2.3 76 0.03 3.7 77.5 0.05 3.8 75.1 0.05
 60 Y F, multiple myeloma, IgA lambda 2.4 6.7 0.36 3.9 6.9 0.57 3.5 6.5 0.54
 70 Y F, multiple myeloma, IgA lambda 2.6 8.1 0.32 4.8 8.7 0.55 3.5 8.2 0.43
 39 Y M, multiple myeloma, IgG lambda 2.6 8.6 0.30 6.3 6.8 0.93 4 8.7 0.46
 60 Y M, hairy cell leukemia 19.1 18.7 1.02 26.1 19.6 1.33 21.8 19.7 1.11
 62 Y M, biclonal IgG kappa + lambda light chaina 3.1 1195 <0.01 4.7 1275 <0.01 3.4 1103 <0.01
 66 Y F, multiple myeloma, lambda light chaina 17.0 296 0.06 19.7 263 0.08 19.3 359 0.05
Discrepancy involving kappa and lambda
 53 Y F, multiple myeloma, IgG kappa 18.9 24.7 0.77 21.9 25.0 0.88 21.9 26.6 0.82
 84 Y M, multiple myeloma, lamba light chain 2.9 5.6 0.52 3.0 6.8 0.44 3.5 5.3 0.66
 51 Y M, multiple myeloma, IgG kappa 1.8 5.5 0.33 3.6 6.9 0.52 2.9 6.8 0.43
Discrepancy involving kappa and kappa/lambda ratio
 54 Y F, multiple myeloma, kappa light chain 1.4 7.2 0.19 3.5 7.6 0.46 2.5 7.6 0.33
Discrepancy involving kappa/lambda ratio
 67 Y M, multiple myeloma, IgG kappa 29.1 18.3 1.59 34.4 18.4 1.87 29.3 18.5 1.58
 64 Y M, multiple myeloma, kappa light chain 21.9 13.8 1.59 23.7 14.9 1.59 25.1 13.9 1.81
 57 Y F, multiple myeloma, IgG lambda 25.1 15.7 1.60 27.7 15.6 1.78 26.2 15.5 1.69
 55 Y M, multiple myeloma, lambda light chain 12.1 7.4 1.64 14.8 7.5 1.97 13.9 7.4 1.88
 59 Y M, Waldenstroms, IgM lambda 19.8 12.6 1.57 22.7 12.7 1.79 23.5 12.9 1.82
PST plasma separator tube
a Also identified as outlier for lambda light chain analysis by Deming regression (Table 4)
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Discussion
Overall, EDTA-plasma and lithium heparin-plasma gave 
comparable results to serum for kappa light chain con-
centration, lambda light chain concentration, and kappa/
lambda ratio for the Freelite™ assays performed on the 
cobas 8000 c502 analyzer. Similar to previous reports 
(Hansen et  al. 2012; te Velthuis et  al. 2011), these data 
suggest that plasma is an acceptable specimen for free 
light chain analysis. The precision, linearity, and analyte 
stability in plasma is also comparable to that described 
for serum in previous publications (Altinier et  al. 2013; 
Briand et  al. 2010; Cha et  al. 2014; Hansen et  al. 2012; 
Pretorius et al. 2012; Tate et al. 2003, 2009; Vercammen 
et al. 2015).
The highest variability seen in our study was with very 
low or very high kappa and lambda concentrations. This 
was evident in the regression outlier analysis. The light 
chain analysis procedure in the package insert for the 
Freelite™ assay on the cobas 8000 analyzers requires two 
dilutions (one on-line and one manual) for the highest 
concentrations (kappa greater than 563 mg/L and lambda 
greater than 933 mg/L). These dilutions offer potential for 
error. At high concentrations of free light chains, antigen 
excess is also possible (Bosmann et al. 2010; Vercammen 
et al. 2015). We did not study antigen excess in detail but 
did observe comparable results with both plasma speci-
men types in a patient previously observed to have hook 
effect with lambda concentrations. Specimens with very 
Table 4 Outliers identified by Deming regression analysis
PST plasma separator tube















 60 Y M, multiple myeloma, kappa light chain 46.1 14.7 3.14 107 15.0 7.16 55.8 14.7 3.80
 59 Y F, multiple myeloma, IgG kappa 6684 6.1 1096 7764 6.1 1273 7125 6.7 1063
 52 Y M, multiple myeloma, IgG kappa 337 11.0 30.6 419 11.1 37.8 415 11.2 37.1
 60 Y M, multiple myeloma, IgG kappa 56.2 10.5 5.35 112 10.3 10.87 91.9 10.8 8.51
 59 Y M, multiple myeloma, IgG kappa 128 6.1 21.03 177 7.2 24.6 197 6.2 31.8
Lambda outliers
 60 Y M, plasma cell leukemia, IgG lambda 4.0 693 0.01 5.7 672 0.01 5.0 621 0.01
 74 Y F, multiple myeloma, IgG lambda 4.4 1590 0.00 6.7 1457 0.00 5.2 1571 0.00
 55 Y F, multiple myeloma, lambda light chain 11.8 1334 0.01 12.7 1747 0.01 12.0 1562 0.01
 65 Y M, multiple myeloma, lambda light chain 9.9 278 0.04 12.5 311 0.04 10.1 278 0.04
 59 Y F, acute renal failure, seropositive rheumatoid arthritis 29.8 36.4 0.82 28.8 27.2 1.06 25.9 27.4 0.95
 62 Y M, biclonal IgG kappa + lambda light chain 3.1 1195 <0.01 4.7 1275 <0.01 3.4 1103 <0.01
 66 Y F, multiple myeloma, lambda light chain 17.0 296 0.06 19.7 263 0.08 19.3 359 0.05
Table 5 Linear regression summary statistics of specimen comparisonsa
a Analysis uses Deming regression excluding outliers (see Table 4)
b CI confidence interval
c MDL medical decision limit: kappa, 3.3 and 19.4 mg/L; lambda, 5.7 and 26.3 mg/L; κ/λ ratio, 0.26 and 1.65
Slope (95 % CI)b Y-intercept (95 % CI)b (mg/L) Correlation coef-
ficient
95 % CI at lower MDLc 
(mg/L)
95 % CI at upper 
MDLc (mg/L)
EDTA vs. serum
 Kappa 0.969 (0.950–0.988) 2.58 (1.54–3.64) 0.9954 4.8–6.8 20.4–22.4
 Lambda 0.995 (0.986–1.003) 0.367 (0.127–0.608) 0.9992 5.8–6.3 26.3–26.7
 κ/λ ratio 1.001 (0.982–1.021) 0.133 (0.066–0.199) 0.9957 0.33–0.46 1.73–1.84
Li-heparin plasma separator tube vs. serum
 Kappa 1.081 (1.063–1.100) 0.64 (−0.38 to 1.67) 0.9964 3.2–5.2 19.4–22.5
 Lambda 0.988 (0.981–1.000) 0.279 (−0.101 to 0.557) 1.0000 5.7–6.3 26.1–26.6
 κ/λ ratio 1.175 (1.154–1.196) −0.091 (−0.188 to 0.007) 0.9961 0.12–0.31 1.65–1.83
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low values of kappa or lambda can also lead to higher 
variability in the kappa/lambda ratio, especially with the 
high imprecision typical of analyses in these low concen-
tration ranges (Altinier et al. 2013; Briand et al. 2010; Cha 
et al. 2014; Hansen et al. 2012; Pretorius et al. 2012; Tate 
et al. 2003, 2009; Vercammen et al. 2015).
While plasma gave comparable results to serum in our 
study, it is probably prudent to use a single specimen 
type and analyzer platform for patient analysis. Refer-
ence intervals and medical decision levels should be reas-
sessed carefully for any specimen type other than serum. 
The trending of light chain values is used for treatment 
decisions and consistency in analysis is important. Future 
studies can focus on different instrument platforms and 
assay formats. A larger set of samples can also facilitate 
detailed studies on how plasma compares with serum 
with respect to antigen excess.
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Fig. 4 Stability of free light chain measurements at different storage conditions. The plot shows the percent change relative to initial analysis for 
kappa (a, b) and lambda (c, d) measurements using EDTA-plasma and lithium heparin plasma separator tube (PST) specimens
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